Source-grounded facts extracted from Nuvectis Pharma, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Nuvectis Pharma, Inc. shareholders approved Ratification of Kesselman & Kesselman as independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-11 meeting.
“The vote with respect to the ratification of Kesselman & Kesselman as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, was as follows: Votes For Votes Against Abstentions / Votes Withheld Broker Non-Votes 15,662,222 10,574 520,890 -”
Nuvectis Pharma, Inc. shareholders approved Election of Class I director to hold office until the 2029 annual meeting at the 2026-06-11 meeting.
“The vote with respect to the election of the Class I director to hold office until the 2029 annual meeting was as follows: Director Votes For Votes Against Abstentions / Votes Withheld Broker Non-Votes Ron Bentsur 8,354,838 391,265 216 7,447,367”
Nuvectis Pharma, Inc. reported financial results for the first quarter ended March 31, 2026.
“On May 5, 2026, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the first quarter ended March 31, 2026.”
Nuvectis Pharma, Inc. reported first quarter ended March 31, 2024 results: net income $4.2 million.
“First Quarter 2024 Financial Results Cash, and cash equivalents were $19.5 million as of March 31, 2024, compared to $19.1 million as of December 31, 2023. The increase of $0.4 million in the cash balance in the first quarter of 2024 is a result of the utilization of the at-the-market facility, partially offset by the operating expenses for the quarter. The Company's net loss was $4.2 million for the three months ended March 31, 2024, compared to $4.0 million for the three months ended March 31, 2023, an increase in net loss of $0.2 million.”
Nuvectis Pharma, Inc. reported the fiscal year ended December 31, 2023 results: net income $22.3 million.
“The Company's net loss was $22.3 million for the year ended December 31, 2023, compared to $19.1 million for the year ended December 31, 2022”
Nuvectis Pharma, Inc. reported financial results for Third Quarter 2023.
“Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights”
Nuvectis Pharma, Inc. reported the second quarter ended June 30, 2023 results: net income $5.7 million.
“Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the second quarter ended June 30, 2023.”
Nuvectis Pharma, Inc. shareholders approved Approval of amendment to Nuvectis Pharma, Inc. Global Equity Incentive Plan (2021) at the 2023-06-16 meeting.
“The vote with respect to the approval of an amendment to the Nuvectis Pharma, Inc. Global Equity Incentive Plan (2021) was as follows: Total Votes For Total Votes Against Abstentions Broker Non-Votes 8,984,698 198,029 2,462 3,284,985”
Nuvectis Pharma, Inc. shareholders approved Ratification of Kesselman & Kesselman as independent registered public accounting firm at the 2023-06-16 meeting.
“The vote with respect to the ratification of Kesselman & Kesselman as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was as follows: Total Votes For Total Votes Against Abstentions Broker Non-Votes 12,468,118 616 1,440 -”
Nuvectis Pharma, Inc. shareholders approved Election of Class I director at the 2023-06-16 meeting.
“The votes with respect to the election of the Class I director to hold office until the 2026 annual meeting were as follows: Director Votes For Votes Withheld Broker Non-Votes Ron Bentsur 9,035,321 149,868 3,284,985”
Nuvectis Pharma, Inc. reported first quarter 2023 results: net income Net loss was $4.0 million for the three months ended March 31, 2023.
“Net loss was $4.0 million for the three months ended March 31, 2023”
Nuvectis Pharma, Inc. reported the fiscal year ended December 31, 2022 results: net income $19.1 million.
“Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the fiscal year ended December 31, 2022”
Nuvectis Pharma, Inc. reported financial results for the third quarter ended September 30, 2022.
“On November 8, 2022, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the third quarter ended September 30, 2022.”
Michael Carson was appointed as Vice President of Finance at Nuvectis Pharma, Inc..
“Michael Carson, who recently joined Nuvectis as Vice President of Finance, is replacing Uri Ben-Or”
Uri Ben-Or departed as Interim Chief Financial Officer at Nuvectis Pharma, Inc..
“Uri Ben-Or who served as the Company's Interim Chief Financial Officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.